Education
About Us
Working with TipRanks
Follow Us
Vaxil Bio Ltd (TSE:VXL)
:VXL
VXL Stock Chart & Stats
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.01
Previous CloseN/A
Volume4.43K
Average Volume (3M)9.69K
Market Cap
C$684.89K
Enterprise ValueN/A
Total Cash (Recent Filing)C$535.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.82
Next Earnings
Jun 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding136,978,970
10 Day Avg. Volume9,686
30 Day Avg. Volume9,686
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Vaxil Bio News
PremiumCompany Announcements
Vaxil Bio Announces Share Consolidation to Optimize Market Position
PremiumCompany Announcements
Vaxil Bio Announces Management Update and Strategic Operational Changes
PremiumCompany Announcements
Vaxil Bio and Green Data Centers Terminate AgreementPremiumCompany Announcements
Vaxil Bio Announces Strategic Acquisition of Green Data Centers
PremiumCompany Announcements
Vaxil Bio Announces Potential Reverse Takeover
PremiumCompany Announcements
Vaxil Bio Advances Cancer Research Post-Takeover Termination---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was <C$0.01 and its highest was C$0.01 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$684.89K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Jun 02, 2025 which is in 20 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Currently, no data Available
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 136,978,970 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
---
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
---
NanoSphere Health Sciences Inc
―
Biocure Technology Inc
―
Waverley Pharma
―
HAVN Life Sciences
―
Lophos Holdings, Inc.
―
---